J&J receives subpoenas

US attorneys in Boston, Philadelphia and San Francisco have issued subpoenas to Johnson & Johnson for marketing materials involving three of its subsidiaries—Ortho-McNeil for Topamax, Janssen for Risperdal  and Scios for Natrecor.

J&J said the subpoenas seek information on its corporate supervision and oversight of the subsidiaries. A J&J statement said the company will cooperate.

Janssen, which increased Risperdal sales by 18% to $4.18 billion last year, received a subpoena in 2005 seeking information about the drug’s marketing and adverse reactions. Less than two years earlier, it received a subpoena from the Office of Personnel Management’s inspector-general seeking similar documents.

J&J’s Ortho-McNeil subsidiary, which increased Topamax sales by 21% to $2.03 billion last year, received a subpoena from the US Attorney’s Office in 2003 seeking documents relating to the drug’s marketing, including alleged “off-label” marketing, and a second subpoena last June.

In 2005, Scios received a subpoena from the US Attorney’s Office seeking documents regarding the sales and marketing of Natrecor, and Scios is responding to the subpoena, J&J said in the SEC filing.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions